Last reviewed · How we verify
Oral administration of Lobeglitazone
Oral administration of Lobeglitazone is a Small molecule drug developed by Yonsei University. It is currently FDA-approved.
At a glance
| Generic name | Oral administration of Lobeglitazone |
|---|---|
| Sponsor | Yonsei University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy Volunteers (PHASE1)
- Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers (PHASE1)
- Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers (PHASE1)
- Pharmacokinetics and Safety of M107 Orally Disintegrating Tablet in Healthy Adults (PHASE1)
- Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State. (PHASE1)
- Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150 (PHASE1)
- Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029 (PHASE1)
- Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral administration of Lobeglitazone CI brief — competitive landscape report
- Oral administration of Lobeglitazone updates RSS · CI watch RSS
- Yonsei University portfolio CI
Frequently asked questions about Oral administration of Lobeglitazone
What is Oral administration of Lobeglitazone?
Oral administration of Lobeglitazone is a Small molecule drug developed by Yonsei University.
Who makes Oral administration of Lobeglitazone?
Oral administration of Lobeglitazone is developed and marketed by Yonsei University (see full Yonsei University pipeline at /company/yonsei-university).
What development phase is Oral administration of Lobeglitazone in?
Oral administration of Lobeglitazone is FDA-approved (marketed).